Technology offers timely and cost-efficient infection prevention solution for long-term care amidst industry-wide labor shortagesDALLAS, TX / ACCESSWIRE / April…
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live…
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed…
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for…
WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company…
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health…
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing…
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a…
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for…
Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertiseCollaboration aims to…